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The biologic activities of  the major cleavage product of C3 (C3b) are blocked by 
C3b  inactivator,  a  plasma protein with  a  mol wt  of approximately 100,000 
daltons  (1)  which cleaves  C3b  into two smaller fragments,  C3c and C3d.  A 
second factor which participates in C3b inactivation was provisionally termed 
C3b inactivator accelerator (A. C3bINA)  1 (2), because it potentiated the activity 
of C3b inactivator. The activity of A. C3bINA resides in a  plasma protein (3) 
previously named ~'fllH globulin" because of its electrophoretic mobility (4). We 
now describe the purification and some physicochemical characteristics of ~IH. 
In addition, we show that fllH not only potentiates the inactivation of C3b by 
C3b inactivator but also has two other important regulatory actions. Firstly, it 
possesses a direct C3b inhibitory activity of its own, distinct from C3b inactiva- 
tor; and secondly, it directly inhibits the activity of the alternative pathway 
convertases C3bB and C3bBP formed by the interactions of C3b, properdin (P), 
and factor B (B) in the presence of factor I:). 
Materials and Methods 
Reagents.  The following reagents were obtained from the sources shown: DEAE-cellulose  (DE 
52) and carboxymethyl cellulose (CM 52) (Reeve Angel, Clit'con, N. J.); hydroxyl apatite (Bio-Gel 
HT), Bio Rex 70, precast polyacrylamide gels, dithiothreitol, and sodium dodecyl sulphate (SDS) 
(Bio-Rad Laboratories, Richmond, Calif.); quaternary aminoethyl Sephadex A-50 (QAE-Sephadex 
A-50), sulphopropyl Sephadex G-25 (SP-Sephadex  G-25), Sephadex G-200 and G-75, aldolase, and 
ribonuclease (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.); agarose (Fisher Scientific Co., 
Pittsburgh, Pa.); trypsin, soybean trypsin inhibitor (SBTI),  and five times recrystallized egg 
albumin (Worthington  Biochemical Corp., Freehold, N. J.); zymosan, N-ethyl maleimide (NEMI), 
and epsilon amino caproic acid (EACA) (Sigma Chemical Co., St. Louis, Mo.); diisopropylfluoro- 
phosphate (DFP) (Aldrich Chemical Co., Inc., Milwaukee, Wis.); human or bovine serum albumin 
(Calbiochem,  San Diego, Calif.); human factor XHI (American Red Cross, Bethesda, Md.). 
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AM18976), and an Arthritis Clinical Research Center grant from the Arthritis Foundation. This is 
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' Abbreviations  used in this paper: A, rabbit antibody; A. C3bINA, C3b inactivater accelerator; 
B, factor B; DFP, diisopropylfluorophosphate;  DGVB  ÷÷, mixture of equal volumes of GVB  ÷+ and 
D5W÷+; D5W  ÷+, 5% dextrose in water; E, sheep erythrocytes; EACA, epsilon amino caproic acid; 
GVB  +÷,  0.1% gelatin veronal buffer;  NEMI, N-ethyl maleimide; P,  properdin; SPTI,  soybean 
trypsin inhibitor; SDS, sodium dodecyl sulphate; Z, average number of hemolytic sites formed per 
cell. 
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Buffers.  Isotonic veronal-buffered saline containing 0.00015 M Ca ++, 0.0005 M Mg  ÷+, and 0.1% 
gelatin  veronal  buffer  (GVB++);  5%  dextrose  in  water  containing the  same  concentrations of 
divalent cations (D5W÷+), and a  mixture of equal volumes of GVB ÷+ and D5W ÷÷ (DGVB  ++) were 
prepared (5).  D5W-- and GVB-- were made as described above for D5W +÷ and GVB  +÷, but the 
divalent cations were omitted. A stock solution of 0.086 M EDTA, pH 7.5, was diluted in GVB-  to 
prepare 0.04 M  EDTA GVB-- and 0.01 M  EDTA GVB--. For assays of C3b inactivation, 0.01 M 
EDTA DGVB--, ionic strength 0.0375 and pH 6.0, was used as previously described (6). 
Hemolytic Assays.  Guinea pig C1 (5), human C4 (7), C2 (7), C3 (4), C5 (4), B  (8), I) (8), P  (9), 
and C3b inactivator (1) were purified by previously published techniques. Rat serum (Pel-Freez 
Biologicals, Inc., Rogers, Ark.) diluted 1:15 in 0.04 M EDTA GVB-- served as a source of C3-C9. 
Sheep erythrocytes (E) were sensitized with rabbit antibody (A) and used to produce EAC14 as 
previously described (7).  EAC43 cells bearing limited C3b sites were prepared from EAC14 using 
purified  C2  (50  effective molecules  per cell)  and  limiting amounts  of purified  C3  followed by 
treatment in 0.04 M EDTA GVB-- for 2 h at 37°C (6). EAC14 cells bearing limited numbers of C4b 
sites were  prepared by incubating EAC1  (400 effective C1  molecules per cell) with a  limiting 
concentration of C4 at 30°C for 15 min (7).  EAC43 cells bearing the unstable alternative pathway 
convertase, C3bB, were prepared by exposing EAC43 cells generated with 1,000 effective mole- 
cules of C3 per cell at 30°C for 30 min and a concentration of 5 ×  107/ml DGVB ÷+ to 5 ng of B/ml and 
50 U of I)/ml. When required the convertase on these cells was stabilized (10) by treating them at 
0 ° with 250 ng of P/ml in 0.01 M  EDTA GVB--. 
To determine the average number of hemolytic C3b sites per erythrocyte, 0.1 ml of EAC43 (1 × 
108/ml  DGVB +÷) were incubated for 30 min at 30°C with an equal volume of DGVB ÷÷ containing 
1.0 ~tg of B and 50 U of factor 15. The resulting EAC4-~-B (1)) were then incubated for 60 min at 37°C 
with 0.3 ml of C3-C9.1.5 ml of 0.15 M NaC1 was added, the tubes centrifuged, and the supernatant 
hemoglobin measured spectrophotometrically at 414  nm.  Calculation of the proportion of cells 
lysed  (y),  and  the  average  number of hemolytic  sites  formed  per cell  (Z)  were  performed  as 
previously described (11). 
For the measurement of the inhibition of cell-bound C3b,  equal volumes of EAC43 bearing 
limited C3b sites and test sample were incubated in 0.01 M EDTA DGVB-- at 37°C for 1 h, the cells 
washed once in 0.01  M  EDTA  GVB--,  once in DGVB ÷+,  and the residual average number of 
hemolytic  C3b  sites  determined  as  described  above.  Inhibition  of hemolysis,  which  reflects 
inactivation of C3b, was expressed either as percentage inhibition of hemolytic sites, or alterna- 
tively as Z' units where Z'  =  -ln  (1  -  proportion of C3b lysis inhibited) (12). 
Antisera.  Antisera to human Clq (13),  C4, C3, and C5, and B  (14),  P  (9), and C3b inactivator 
(15) were produced and used in radial immunodiffusion as previously described (14).  Antisera to 
IgG, IgA, IgM,  a2-macroglobulin, transferrin, ~2-glycoproteins I  and III, hemopexin, plasmino- 
gen,  fl-lipoprotein,  and  cholinesterase  were  purchased  from  Behring  Diagnostics,  American 
Hoechst  Corp.,  Somerville,  N.  J.  Specific  F(ab')2 fragments were  prepared  from monospecific 
antisera by the method of Lachmann (16). 
Analytical Procedures.  Immunoelectrophoresis (17) and SDS polyacrylamide gel electrophore- 
sis (18) were performed by standard techniques. 
Analytical ultracentrifugation was performed using a Beckman Model E ultracentrifuge (Beck- 
man Instruments, Inc., Spinco Div., Palo Alto, Calif.). The sedimentation coefficient of ~IH was 
determined during centrifugation runs at 60,000 rpm at 20°C in 0.15 M saline buffered with 0.05 M 
veronal at pH 7.5. To determine the molecular weight of fllH, short-column equilibrium sedimen- 
tation studies were performed in an analytical ultracentrifuge at a speed of 9,900 rpm for 24 h  at 
20°C; a  partial specific volume of 0.733 was assumed. 
For sucrose density ultracentrifugation, linear gradients of 7.5-30% sucrose in DGVB ++ were 
prepared using a  Buchler gradient mixer (Searle Analytic, Inc., Ft.  Lee, N. J.).  Centrifugation 
was performed for 16 h  in a  Beckman Model L  ultracentrifuge at 40,000 rpm and 4°C  using an 
SW50.1 rotor. 0.15-ml samples were collected from the bottom of the gradient and the positions of 
Clq, C4, C3, IgG, and B determined by radial immunodiffusion. The sedimentation characteristics 
offllH in a  NaBr gradient were studied by mixing an equal volume of 5.2 M NaBr with fllH at 4 
~g/ml veronal-buffered saline to  increase the relative density to  1.21  (19),  and centrifuging at 
39,000 rpm for 48 h in a Beckman Model L ultracentrifuge using an SW39 rotor. The top 25% of the 
gradient (potentially lipoprotein rich) was removed using a  Pasteur pipette,  and the lower 75% 
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Protein concentrations of pools from column chromatography and purified preparations of j31H 
were determined using the Folin method (20) with five times recrystallized bovine serum albumin 
as standard. Immunoadsorbents were prepared by linking the adsorbing material to Sepharose 4B 
by the cyanogen bromide technique (21). 
The sensitivity offllH to various chemical and physical treatments was tested as follows: 0.1 ml 
of a  solution of 4  ttg/ml was treated for 15 rain at 37°C with the following reagents at the final 
concentrations shown: 10  -3 M DFP, 100/~g/ml SBTI, 10  -s M NEMI, 10 4 M Is, and 1.0 M EACA. To 
determine the sensitivity of ~IH to heat, 4  ~g/ml DGVB  ++ were incubated at 56°C for 30 min. 
Sensitivity to trypsin was tested by treatment with trypsin, 100 ~g/ml for 5 rain at 37°C followed 
by the addition of 200 ~g]ml of SBTI. 
Results 
Identification  of A .C3bINA  Activity  in Normal  Serum.  Because  it  was 
repeatedly observed that  purified C3b  inactivator had  less  C3b-inactivating 
activity than the same concentration of C3b  inactivator contained in whole 
serum, other substances in plasma, distinct from C3b inactivator, which could 
either inactivate C3b directly or potentiate the effect of C3b inactivator, were 
sought. 2.5 ml of normal human serum were chromatographed on a 2.5 x 90 cm 
column of Sephadex G-200 in 0.05 M veronal-buffered isotonic saline, pH 7.5, 
containing 0.01 M  EDTA.  Direct C3b-inactivating activity was measured by 
testing fractions with EAC43 bearing 0.8 C3b sites per cell as described in the 
Materials and Methods. A single peak of C3b-inactivating activity eluted syn- 
chronously  with C3b inactivator protein detected  by radial immunodiffusion  at a 
volume corresponding to  a  mol wt of approximately 100,000 (Fig.  1).  When 
fractions were tested for their ability to potentiate the C3b inactivation reaction 
by including 0.4 U of purified C3b inactivator/ml in the assay, a second peak of 
activity appeared between the 19S and 7S protein peaks in a position correspond- 
ing to an approximate mol wt of 300,000 daltons; this was not associated with 
C3b inactivator protein. The active principal in this early peak, which, under 
the conditions of the assay, possessed no direct C3b-inactivating activity of its 
own but potentiated the inactivation of C3b by the C3b inactivator, was tenta- 
tively named the C3b inactivator accelerator (A. C3bINA). 
Purification  ofA .C3bINA.  5 U  of fresh frozen plasma were thawed and 
recalcified; clotting was allowed to proceed at 4°C overnight. Atter separation 
from the fibrin clot, the serum was dialyzed against 0.008 M EDTA, pH 7.5. The 
precipitate was separated by centrifugation, and the pH of the supernate re- 
duced to 6.5 by the addition of 1.0 N HC1. Aider 2 h at 4°C, the precipitate was 
separated by centrifugation, washed once, redissolved in 0.75 M sodium chloride 
buffered with 0.25 M veronal at pH 7.5, and dialyzed against 0.01 M Tris HC1 
containing 0.002 M  EDTA, pH 7.5, with sufficient added NaC1 to adjust the 
conductivity to  5.0  mS at 0°C. The dialyzed sample was applied to  a  QAE- 
Sephade.x A-50 column (2.5 ×  100 cm) equilibrated with the same buffer. The 
column was washed with one column volume of buffer, and then eluted with a 
linear NaC1 gradient increasing to 0.7 M NaC1. As assessed by radial immuno- 
diffusion, C3b  inactivator eluted with the starting buffer, behind the initial 
peak of unadsorbed protein. Using the A. C3bINA assay, two major peaks of C3b 
inactivation were observed. The first corresponded to C3b inactivator protein, 
and the second eluted with the gradient at a conductivity of 11.0 mS (0°C) (Fig. 
2a). This second peak (fractions 105-115) was concentrated to 15 ml by ultrafil- 1150  MODULATION  OF  THE  ALTERNATIVE  COMPLEMENT  PATHWAY 
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FIG.  ].  Sephadex G-200 chromatography of normal human serum.  2.5 m] of serum were 
applied to a 2.5 x  90 cm column. Fractions were assayed for OD280 (  .... ), Z' units of direct 
C3b-inactivating activity (O---O), Z' units ofC3b inactivator-potentiating activity (Q--a), 
and presence of C3b inactivator protein (_+ at top). RID, radial immunodiffusion. 
tration, dialyzed against 0.02 M phosphate buffer, pH 7.0,  and applied to a Bio 
Rex  70  column  (2.5  x  35  cm) equilibrated  with  the same buffer.  After the 
appearance of the unadsorbed protein,  a  linear NaC1  gradient of 0.7 M  was 
applied.  A.C3bINA  eluted at  11.0  mS  (0°C) with  the  bulk  of the  adsorbed 
protein. The A. C3bINA pool (fractions 73-77)  was concentrated by ultrafiltra- 
tion  and  chromatographed on  a  Sephadex  G-200  column  (2.5  x  100  cm)  in 
veronal-buffered saline from which it eluted with an apparent mol wt of 300,000 
daltons (Fig. 3). The final pool was concentrated by ultrafiltration to a protein 
concentration of 395 ~g/ml. 
Properties of Purified A.C3bINA.  In polyacrylamide gel electrophoresis, 
using 0.188  M  Tris-glycine buffer, pH 8.9,  purified A. C3bINA failed to enter 
7.5% gels, and only partially entered 4% gels, forming a smear near the origin. 
Incubation ofA. C3bINA with 2% SDS and 8.0 M urea at 37°C for 2 h followed by 
electrophoresis in 4% acrylamide and 0.2% SDS resulted in the presence of a 
single  dense  band  alter  staining  with  Coomassie  blue  (Fig.  4).  This  band 
contained 93% of  the stain as determined by densitometry. As judged by compar- 
ison  with  standards  of human  serum  albumin  and  its  polymers,  aldolase, 
ovalbumin, and RNase, the position of the A. C3bINA band corresponded to an 
approximate mol wt of 150,000 daltons.  The appearance of the band was not 
altered by prior reduction with 0.2 M 2-mercaptoethanol or 0.1 M dithiothreitol 
in 8.0 M urea followed by incubation with 0.2 M iodoacetamide, suggesting that 
A. C3bINA  is  a  single  polypeptide  chain.  The  band  stained  heavily in  the 
periodic acid-Schiff (PAS) reaction which indicated that it contained a  signifi- 
cant quantity of carbohydrate. 
In the analytical ultracentrifuge at a concentration of 367 ~g A. C3bINA/ml a 
single sharp peak was observed which had a  sedimentation coefficient of 5.6. 
This value was unaltered when the protein concentration was reduced to 183.5 
~g/ml. By sucrose density gradient ultracentrifugation, the sedimentation coef- mS(O°C) 
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Fro.  2.  Purification of A. C3bINA. (a), QAE-Sephadex A-50 separation of pH 6.5 euglobu- 
lin of  human serum. Fractions were assayed for A- C3bINA activity as described in the text. 
Two major peaks  of C3b  inactivation were seen;  the  early peak,  corresponding to  C3b 
inactivator (C3bINA)  protein, eluting with the starting buffer; and the second,  presumed 
A. C3bINA, eluting at 11.0 mS at 0°C. RID, radial immunodiffusion. (b),  A. C3bINA peak 
from QAE-Sephadex A-50 rechromatographed over Bio Rex 70. Fractions were assayed for 
A.C3bINA  activity.  The  single  peak  of activity eluted  at  11.0 mS  (0~C) and  did  not 
correspond to C3b inactivator (C3bINA) protein. RID, radial immunodiffusion. 
ficient of A. C3bINA was 6.4.  In NaBr ultracentrifugation  A. C3bINA did not 
float, indicating a density of >1.21. By equilibrium sedimentation in the ultra- 
centrifuge,  a mol wt of 150,000  daltons was determined. 
A. C3bINA activity was completely destroyed by trypsin. Heating to 56°C for 
30 min  resulted in approximately 30%  loss of activity.  DFP,  SBTI, NEMI,  or 
iodine were without effect. Because EACA directly inhibited  C3b inactivator 
activity, it was impossible to assess its effect on A. C3bINA. 
Production of Antiserum to A .C3bINA.  New Zealand white rabbits were 
immunized  subcutaneously  with  100  ~g  of purified  A.C3bINA  in  Freund's 1152  MODULATION  OF  THE  ALTERNATIVE  COMPLEMENT  PATHWAY 
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FIG.  3.  Sephadex G-200 gel  filtration of purified A.C3bINA.  OD~o  peak  (0---0) corre- 
sponded  with A. C3bINA activity.  The elution  volumes of proteins of known  molecular 
weight are shown above. A. C3bINA eluted with an apparent mol wt of 300,000 daltons. 
complete adjuvant. 6 wk later, the animals were reimmunized intravenously 
with 100  ~g of A. C3bINA,  and they were bled 7,  10,  and 14 days later. On 
immunoelectrophoresis  against whole human plasma, the antiserum produced a 
dense arc in the fl-region and a  faint arc in the a-region. Analysis of various 
fractions of serum indicated that the protein with a-mobility was present in 
high concentration in the pH 5.4 pseudoglobulin, and that the protein with fl- 
mobility was virtually absent from this fraction. Since preliminary experiments 
had shown that A. C3bINA activity had a fl-mobility in agarose at pH 8.3, the 
antiserum was adsorbed with insolubilized pH 5.4 pseudoglobulin to render it 
specific for the protein of B-mobility. In immunoelectrophoresis, this antiserum 
reacted both with normal human plasma and purified A-C3bINA to yield a 
single arc in the fl-region (Fig. 5) which trailed toward the origin. When agarose 
strips were cut from the same electrophoresis plate, eluted with DGVB ÷+, and 
the eluates tested for A. C3bINA activity, the position of this activity corre- 
sponded to the precipitin arc. 
In double diffusion against normal human serum in agarose gel, the antise- 
rum to A. C3bINA gave reactions of nonidentity with antisera to Clq, C4, C3, 
B, P, C5, C6, C7, C8, Ci inhibitor, C3b inactivator, fl2-glycoproteins I and HI, fl- 
lipoprotein, hemopexin, cholinesterase, a2-macroglobulin, plasminogen, trans- 
ferrin, IgG, IgA, or IgM. No reaction between the antiserum and purified factor 
XIII was observed. A reaction of identity with antibody to fllH globulin was KEITH  WHALEY  AND  SHAUN  RUDDY  1153 
Fro.  4.  SDS polyacrylamide gel electrophoresis of purified A. C3bINA; stain, Coomassie 
blue.  93%  of the  stain  was  in  the  A.C3bINA  band  as  determined  by  densitometry. 
A. C3bINA band corresponded to an approximate mol wt of 150,000 daltons. The position of 
a  RNase marker is shown. 
initially found by Dr. Chester Alper, Center for Blood Research, Boston, Mass., 
and  subsequently  confirmed  by Dr.  Ulf Nilsson,  School  of Dental  Medicine, 
University  of Pennsylvania,  Philadelphia,  Pa.  fllH was  first  described  as  a 
prominent contaminant of  both C3 and C5 preparations (4). A purified sample of 
fllH from Dr. Nilssen's laboratory had the same electrophoretic, ultracentrifu- 
gal,  functional,  and  antigenic properties as our preparations.  For the sake of 
both simplicity  and  historical  accuracy,  therefore,  the  name  C3b inactivator 
accelerator has been discarded and ]]IH used in its place. 
Using monospecific antiserum to fllH we were able to measure the degrees of 
purification and yields of fllH at various stages during the preparative  proce- 
dures (Table I). From 1,120 ml of plasma, containing 133 #g of fllH/ml, 2.20 mg 
of purified fllH were obtained, which is a yield of 1.48%.  Since by densitometry 
only 93% of the Coomassie blue stain was in the fllH band on SDS polyacryl- 
amide gel electrophoresis, we have assumed that the preparation  is 93% homo- 
geneous, and that the B1H was purified by a factor of 376.5. 
Activity of fllH.  The ability of fllH to potentiate the inactivation of C3b by 
purified C3b inactivator was assessed in the following experiment.  Two sets of 
EAC43 bearing 0.83 hemolytic C3b sites per cell were incubated at 5  ×  10~/ml 
0.01  M  EDTA  DGVB--  in  the  presence  of varying  concentrations  of B1H, 
ranging from 0 to 5 ~tg/ml.  One set of cells was incubated with fllH alone, and 
the other with 0.2 Z' U/ml of C3b inactivator in the presence of fllH. At the end 
of 60 min incubation  at 37°C,  the extent of C3b inhibition  was determined  as 
described in the Materials and Methods. In the absence of C3b inactivator,  fllH 
produced some dose-dependent inhibition of C3b (Fig. 6).  C3b inactivator alone 
reduced the  total  number  of hemolytic  sites from  0.83  to  0.69.  The  extent  of 
inhibition  of C3b produced by C3b inactivator  and  fllH  together  greatly  ex- 
ceeded the sum of those achieved independently,  demonstrating  a  synergistic 
effect between these proteins in the inactivation of C3b. 
Kinetics  of Inactivation  of C3b and C3b Inactivator  and fllH.  Five sets of 
EAC43 bearing 1.1 C3b sites per cell (1 ×  108/ml in 0.01 M EDTA DGVB--) were 
incubated at 37°C with buffer alone, normal serum diluted 1:1,000,  purified C3b 
inactivator containing the same concentration of C3b inactivator as present in 
the dilution of normal serum,  fllH (400 ng/ml),  and fllH with C3b inactivator 
together.  Samples were removed from the reaction mixtures at timed intervals, 
diluted on ice-cold 0.01 M EDTA GVB--, and centrifuged. The cells were washed 
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FIG.  5.  Agarose gel electrophoresis  of A. C3bINA. Upper well, purified A. C3bINA; lower 
well, normal plasma. A. C3bINA antiserum in upper trough and anti-normal human serum 
in lower trough. The antiserum produced a single arc in the E-region, which trailed into the 
origin.  Slices were cut from the agarose,  eluted,  and the  eluates tested for A-C3bINA 
activity as shown in the upper frame. A. C3bINA activity corresponded to immunoprecipit- 
able protein. 
TABLE  I 
Purification  of fllH 
Purity ~IH con- 
Total protein  B1H concen-  Yield at each  centration/protein  Purification 
Pool  Volume  concentration  tration  stage  concentration  factor 
ml  pg/rnl  ,ug/ml  % 
Plasma  1,120  53,800  133  100.0  2.47  ×  10 3  _ 
Euglobulin, pH 6.5  135  8,500  490  44.4  5.76  ×  10 2  23.3 
QAE-Sephadex A-50  15  2,100  741  16.8  3.53 x  10  :  142.9 
Bio Rex 70  3  2,200  1,367  36.9  6.21 ×  10  -~  251.4 
Sephadex G200  6  395  307  57.8*  9.30 ×  10rt$  376.5 
* Total yield of ~81H: 2.20 mg, 1.48%. 
This factor is based on densitometric studies of purified B1H on SDS acrylamide gel electrophoresis. 
measured. The kinetics of inactivation of C3b (Fig.  7) by C3b inactivator alone, 
C3b  inactivator  and  fllH  together,  and  normal  serum  were  all  first  order, 
suggesting that  the  potentiation  of C3b  inactivator by fllH is not a  multistep 
process,  fllH  alone  produced  a  small  amount  of inactivation  of C3b  but  the 
extent of this precluded firm conclusions as to the kinetics of this reaction. 
Requirements for the Simultaneous Presence of flIH and C3b Inactivator for 
the Potentiation of C3b Inactivation.  Four identical aliquots of EAC43 bearing 
1.1.  C3b sites per cell (1  ×  108/ml in 0.01 M  EDTA DGVB--) were incubated at 
37°C for 1 h  in the presence of either buffer alone,  C3b inactivator alone (0.4 Z' 
U/ml,/~IH alone (400 ng/ml), or/~IH plus C3b inactivator. The tubes were then 
centrifuged,  the  cells washed  in  0.01  M  EDTA DGVB--,  resuspended  to their 
original volume, and reincubated for a  second hour at 37°C.  For the second hour 
of incubation, the sample initially exposed to C3b inactivator alone was divided 
into two portions, one of which was incubated in buffer and the second with fllH KEITH WHALEY  AND  SHAUN  RUDDY 
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Fro.  6.  Direct C3b inhibitory, and C3b inactivator-potentiating  activities of fllH. EAC43 
were incubated with increasing concentrations of BIH (0-5 ~g/ml), in the absence (upper 
line) or presence of a limited concentration of purified C3b inactivator (lower line). ~IH 
produced dose-dependent inhibition  of C3b, and also potentiated the inactivation  of C3b by 
C3b inactivator. 
alone.  Cells  originally  exposed to  BIH alone  were likewise divided  into  two 
portions,  one being incubated with buffer and the other with C3b inactivator 
alone. Those cells incubated with C3b inactivator and/~IH together during the 
first hour were incubated with buffer.  Cells incubated with buffer during the 
first hour were reincubated with buffer for a  second hour. 
C3b inactivator alone produced 48% inactivation  of C3b and B1H alone pro- 
duced 4% inactivation  (Fig. 8). Either C3b inactivator followed by fllH, or B1H 
followed by C3b inactivator yielded inactivation similar to the sum of the values 
for  C3b  inactivator  and  B1H,  irrespective  of the  sequence  in  which  these 
reagents  were  used.  In  contrast,  when  cells  were  exposed to  fllH  and  C3b 
inactivator simultaneously, 87% inactivation was achieved. 
Comparison of  Effects on C3b and C4b.  C4b is inactivated by a C4b inactiva- 
tor, a  plasma protein which has not been separated from C3b inactivator  (22). 
The ability of purified C3b inactivator to inactivate cell-bound C3b and C4b, and 
for fllH to potentiate these effects were compared in the following experiments. 
EAC43  and  EAC14  bearing  1.1  and  1.0  hemolytic  sites,  respectively,  were 
incubated with varying concentrations of purified C3b inactivator with or with- 
out a fixed input of B1H (400 ng/ml).  After incubation at 37°C for 1 h in 0.01 M 1156  MODULATION  OF  THE  ALTERNATIVE  COMPLEMENT  PATHWAY 
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Fro.  7.  Kinetics of inactivation  of C3b by normal human .serum diluted  1:1,000 (O--O), 
purified C3b inactivator  at the same concentration as present in serum (m--m), B1H alone 
400 ng/ml (©--©), and C3b inactivator together with ~IH (A--A). 
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FIG.  8.  Requirement for the simultaneous presence of C3b inactivator  (C3bINA)  and fllH 
for the ~IH potentiation  effect. EAC43 were incubated at 37°C for 1 h, with the reagents 
shown in the upper line. After washing, they were reincubated at 37°C with the reagents 
shown on the lower line. C3b inactivator alone, C3b inactivator followed by/31H, and fllH 
followed by C3b inactivator,  all produced similar degrees of C3b inactivation.  Significant 
potentiation was only seen when C3b inactivator and fllH were incubated simultaneously. 
EDTA DGVB--, the cells were washed twice in DGVB  ++ and resuspended to 1 x 
108/ml DGVB  ÷+. The residual C3b sites on EAC43 were developed as previously 
described.  Residual C4b sites on EAC4 produced from the EAC14 by the expo- 
sure to EDTA were developed by incubation with C1  (200 U/ml) for 15 min at 
30°C, C2 (50 U/ml) for 15 min at 30°C, and finally, in C3-C9 for 1 h at 37°C. C3b 
inactivator alone produced marked dose-dependent inactivation of C3b but had 
little effect on C4b (Fig. 9). As anticipated, fllH produced considerable potentia- 
tion  of C3b  inactivation,  but  little  enhancement  of the  small  degree  of C4b 
inactivation was observed. 
In the  converse experiment  (Fig.  10),  the  input  of fllH  was  varied  in  the 
presence  or  absence  of sufficient  C3b  inactivator  to  induce  almost  identical KEITH  WHALEY  AND  SHAUN  RUDDY  1157 
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FIG. 9.  Inactivation of C3b and C4b by varied inputs of C3b inactivator and a fixed input of 
filH  (400 ng/ml).  EAC43  showed  significant dose-dependent  inhibition  of C3b  by  C3b 
inactivator alone (Q--O); ~IH markedly enhanced this response (@--@). Little inactiva- 
tion of C4b was  achieved with high inputs of C3b inactivator (A--A) and  ~IH did not 
significantly enhance this effect (A--A). 
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FIG.  10.  Inactivation of C3b and C4b by a fixed input of C3b inactivator and varied inputs 
of filH. The inputs of C3b inactivator were adjusted to produce similar degrees of inactiva- 
tion of C3b (0.4 Z' U/ml) and C4b (40 Z' U/ml). fllH produced dose-dependent enhancement 
of C3b inactivation by C3b inactivator (@--@), and dose-dependent inhibition of C3b on its 
own (Q--C). Little potentiation of the inactivation of C4b by C3b inactivator (A--A), and 
no direct C4b inhibition (A--A) were observed. 
degrees of inactivation of C3b and C~b in the absence of fllH. The input of C3b 
inactivator  required  to  achieve  43%  inactivation  of C3b  was  0.4  Z'  U/ml, 
whereas that required to produce 52% inactivation of C4b was 40 Z' U/ml. Dose- 
dependent potentiation of C3b inactivation was observed when fllH was added 
to the reaction mixtures, but the extent of  inactivation of C4b by C3b inactivator 
was relatively independent of fllH concentration. Significant inhibition of C3b 
by high concentrations of fllH in the absence of C3b inactivator was observed. 
Direct Effect of fllH on C3b.  The observations (Figs. 6-10) that high concen- 
trations of B1H inhibited C3b in the absence of C3b inactivator suggested that 
either ~IH had a  direct C3b inhibitory activity or the preparation of B1H was 
contaminated with a small amount of C3b inactivator. To discriminate between 
these possibilities, the following experiment was performed. Four Z' U  of C3b 
inactivator and 20 ~g of fllH were incubated for 15 min at 37°C with an equal 
volume of F(ab')2 fragments prepared from 5 ml of anti-/31H or anti-C3b inacti- 
vater  or  with  buffer.  The  mixture  was  then  diluted  and  the  residual  C3b 1158  MODULATION  OF  THE  ALTERNATIVE  COMPLEMENT  PATHWAY 
inhibitory activity was determined by the inhibition of lysis using the standard 
assay in which EAC43 were exposed to the mixtures, washed, and developed 
with  B,  f),  and  C3-C9.  Anti-B1H  removed  virtually  all  of the  direct  C3b 
inhibitory activity of ~IH, whereas anti-C3b inactivator had little effect (Table 
II).  Conversely, the anti-C3b inactivator removed almost all C3b  inactivator 
activity; but anti-fllH yielded insignificant inhibition. Controls indicated that 
neither F(ab')2 fragments had any effects on the assay system. In other experi- 
ments,  anti-fllH removed  the  C3b  inactivator-potentiating activity of fllH. 
Since the direct C3b  inhibitory and C3b  inactivator-potentiating activities of 
fllH were neutralized by specific anti-fllH but not by anti-C3b inactivator, both 
of these activites reside in the same molecule, fllH. 
Effect  of  fllH  on  the  Alternative  Pathway  Convertases,  C3bB  and 
C3bBP.  The  capacity  of B1H  to  inhibit  a  preformed  alternative  pathway 
convertase was assessed. EAC43 prepared with 1,000 effective molecules of C3 
per cell were incubated at 1 x  108/ml DGVB  ++ for 30 min at 30°C in the presence 
of 5 ng/ml B  and 50 U/ml of I) to allow the formation of EAC43bB.  The cells 
were then centrifuged, washed once in ice-cold DGVB  ++, resuspended to 1 x  108/ 
ml  in  0.01 M  EDTA  GVB--,  and exposed to  250  ng of P/ml at 0°C  to form 
EAC43bBP. After 3 min at 0°C to allow for binding of P to the EAC43bB, the 
cells were divided into two portions, one of which received 80 ng/ml of fllH and 
the  other  buffer.  Both  mixtures  were  then  incubated at  30°C and  at  time 
intervals 0.1-ml portions were sampled into 0.4 ml of C3-C9 for a further 60-min 
incubation at 37°C. The half-life of the EAC43bBP suspended in buffer was 17 
min, whereas EAC43bBP suspended in ~IH exhibited a marked increase in the 
rate of loss of hemolytic sites (Fig. 11). When EAC43 cells were pretreated with 
the same concentration of ~IH before exposure to B, I), and P for the formation 
of EAC43bBP, fewer hemolytic sites were observed at time zero, but no increased 
rate  of decay  resulted.  In  other  experiments,  EAC43bB  bearing  the  labile 
convertase also exhibited an increased rate of decay upon exposure to 131H. For 
both convertases, increase in rate of decay was a function of the concentration of 
fllH. 
By  contrast,  C3b  inactivator  had  no  effect  on  the  preformed  alternative 
pathway convertase, as demonstrated in the following experiment. EAC43bBP 
prepared with 1.5 C3b sites per cell,  10  ~g B, 50 U  I),  and 250 ng P/ml were 
decayed at 30°C as described in the preceding experiment except that 80 Z' U 
C3b inactivator were substituted for the B1H. No difference was observed in the 
rate of decay of EAC43bBP in the presence or absence of C3b inactivator (Fig. 
12).  As expected,  treatment of the  EAC43b  with C3b  inactivator before  the 
formation of  the convertase resulted in a decrease of  total hemolytic sites at time 
zero, but no increase in the rate of  decay of  the EAC43bBP formed on subsequent 
exposure to B, I), and P was observed. 
Discussion 
In this paper we have presented evidence that in addition to C3b inactivator 
there exists in human plasma a second protein which modulates the alternative 
complement pathway  (Fig.  1).  On  the  basis  of'its ability to  potentiate the 
inactivation of C3b  by the  C3b  inactivator, we originally named this second KEITH  WHALEY  AND  SHAUN  RUDDY 
TABLE  II 
Inhibition of C3b Inhibitory Activities of BIH and C3b Inactivator by 
Specific F(ab') 2  Fragments 
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Reaction mixture 
Z' units observed 
Buffer  F(ab')2 anti-C3b 
inactivator  F(ab')2 anti-fllH 
Buffer  0  0  0 
fllH  0.70  0.66  0.07 
C3b Inactivator  0.72  0.05  0.66 
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FIG.  11.  Effect of ~IH on the rate of loss of hemolytic sites from EAC3bBP.  EAC43bBP 
were  incubated  at  30°C  in  the  presence  or  absence of fllH  (80  ng/ml).  ~IH  markedly 
increased the rate of loss of hemolytic sites. In contrast when EAC43 were treated with B IH 
before the formation of EAC3bBP, fewer hemolytic sites were found, but the rate of loss of 
sites was the same as found with the untreated cells. 
protein the C3b inactivator accelerator (A. C3bINA). An antiserum to purified 
A. C3bINA  gave  a  reaction  of identity  with  anti-flirt;  B1H being  a  plasma 
protein  without  known  function,  named  on  the  basis  of its  electrophoretic 
mobility (4). For the remainder of the discussion we will use fllH in preference 
to A. C3bINA. 
fllH was purified  from the  pH  6.5  euglobulin  of normal  human  serum  by 
sequential chromatography on QAE-Sephadex A-50, Bio Rex 70, and Sephadex 
G-200 (Figs. 2 and 3). The final yield was 1.48% and the purification 376.5-fold 
(Table I). Three criteria for purity were: a  single band on SDS polyacrylamide 
gel electrophoresis (Fig. 4),  a  homogeneous peak in the analytical ultracentri- 
fuge, and the ability of the purified protein to produce an antiserum with a high 
degree of specificity. After the removal by immunoadsorption of a trace contami- 1160  MODULATION  OF  THE  ALTERNATIVE  COMPLEMENT  PATHWAY 
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FIG. 12.  Effect  of C3b inactivator on the rate of loss of hemolytic  sites from EAC43bBP. 
EAC43bBP were incubated  at 30°C in the presence (0--0) or absence (O--O) of 80 Z' U/ml 
of purified C3b inactivator. C3b inactivator did not influence  the rate of loss of hemolytic 
sites. When EAC43 were pretreated with C3b inactivator (A--&), fewer hemolytic  sites 
were detected  but the rate of loss of sites was unchanged. 
nant  in  the  a-region,  the  anti-fllH  was  monospecific  (Fig.  5).  On  agarose 
electrophoresis,  ~IH activity was congruent with immunoprecipitable protein 
(Fig. 5), and F(ab')2 fragments prepared from the anti-BIH antiserum removed 
this activity (Table II). 
On the basis of trypsin sensitivity, fllH is a protein. Since reduction with 0.2 
M 2-mercaptoethanol or 0.1 M dithiothreitol failed to alter the number of bands 
observed during SDS polyacrylamide gel electrophoresis, ~IH must be a single 
polypeptide chain.  The  PAS-positive  nature  of the  band  suggests that  fllH 
contains a  significant quantity of carbohydrate. The tool wt of BIH was deter- 
mined to be  approximately 150,000 daltons, both by SDS  polyacrylamide gel 
electrophoresis and by equilibrium sedimentation in the analytical ultracentri- 
fuge. Its elution pattern from Sephadex G-200 corresponds to an approximate 
mol  wt  of 300,000 daltons.  This  discrepancy  suggests  that  the  molecule  is 
asymmetric.  Since  the  same  sedimentation coefficient of 5.6S  was observed 
during ultracentrifugation at two different ~IH concentrations, this assymetry 
may be rigid rather than subject to random coil formation as, for example, is 
DNA. The sedimentation coefficients determined in the analytical ultracentri- 
fuge, 5.6,  and in sucrose density gradients, 6.4,  are consistent with a tool wt of 
150,000,  assuming a  partial specific volume of 0.733.  Since the total carbohy- 
drate  content  of fllH  is  at  present  unknown,  the  correct  tool  wt  may  be 
significantly lower than 150,000 daltons. 
fllH appears to potentiate the inactivation of C3b by C3b inactivator (Figs. 1 
and 6-10),  to prevent the fruitful interaction of C3b with C5 in the classical and 
B in the alternative pathways (3), and to diminish the activity of the preformed 
alternative pathway convertases, C3bB and C3b--b-B-P, by increasing their rate of KEITH  WHALEY  AND  SHAUN  RUDDY  1161 
decay (Fig.  11). That these activities belong to the same molecule is shown by 
the ability of immunochemically purified fllH to produce them, and the reversal 
of effects on C3b and C3b inactivation by specific F(ab')2 fragments of anti-filH 
(Table II). In its effects on C3b, ~IH resembles C3b inactivator by modulating 
both classical and alternative  pathways.  In contrast,  however, fllH is able to 
inhibit the preformed alternative pathway convertases C3bB and C3bBP (Fig. 
IlL  whereas  C3b  inactivator  is  without  effect once  C3b has  interacted  with 
factors  B,  I~,  and  P  (Fig.  12).  Another  point  of differentiation  is  that  C3b 
inactivator is able to block immune adherence (23), whereas preliminary studies 
indicate that fllH does not possess this function. 
The ability of ~IH to enhance the inactivation  of C3b by C3b inactivator  is 
reminiscent of the action of a  "10S globulin" to induce cleavage of C4b by C3b 
inactivator  (24).  Further similarity is the necessity for the simultaneous pres- 
ence of C3b inactivator  with either  fllH (Fig.  8) or the  10S globulin for these 
effects. Although  we have not studied the cleavage of C4b,  ~IH only weakly 
potentiates the inactivation of C4b by C3b inactivator (Figs. 9 and 10). A further 
difference  is  the  sedimentation  coefficient of 6.4  for  fllH  on  sucrose  density 
gradients.  Evidence to date suggests that fllH is not the 10S globulin although 
appropriate neutralization studies with specific antibodies need to be performed. 
In a search for an inhibitor of the preformed alternative pathway convertase, 
Fearon et al.  (unpublished data and personal communication) have identified a 
protein with this effect; an antiserum to this protein gives a reaction of identity 
with our anti-flirt. A "C5-site generation inhibitor" present in guinea pig serum 
was  described  in  1969  by Okada  et  al.  (25).  This  inhibitor  could bind  with 
EAC1423 to block C5 activation, but had no effect on immune adherence. These 
facts, together with a similar elution profile on Sephadex G-200, suggest that the 
C5-site generation  inhibitor is the guinea pig analogue of fllH. 
The  mechanism  of action  of B1H is not yet understood,  but the  available 
evidence suggests  that  it  binds  with  C3b.  Kinetic  studies  in  which  both the 
initial rate and final extent of C3b inhibition are proportional to B1H concentra- 
tion suggest a  stoichiometric binding rather  than  an enzymatic reaction.  The 
failure of known enzyme inhibitors such as DFP, SBTI, NEMI, and I2 to block 
fllH activity is consistent with this interpretation.  Furthermore,  EAC43 incu- 
bated with fllH and then washed become agglutinable by anti-fllH  (3). Studies 
are  currently underway to investigate  the mechanism  of interaction  between 
C3b and ~IH. 
Summary 
C3b inactivator  accelerator  (A. C3bINA) was isolated from human  plasma. 
An antiserum produced against the purified protein gave a reaction of identity 
with B1H, a  well-documented contaminant  of C3 preparations,  fllH appears to 
be composed of a  single polypeptide chain containing a  significant quantity of 
carbohydrate,  and having a  sedimentation coefficient of 5.6 on analytical,  and 
6.4 on sucrose density gradient  ultracentrifugation.  Its mol wt based on SDS 
polyacrylamide gel electrophoresis and  equilibrium  sedimentation  is approxi- 
mately 150,000,  whereas it elutes from Sephadex G200 with an apparent mol wt 
of 300,000,  suggesting that B1H is an asymmetric molecule. 
fllH potentiates the inactivation of C3b by C3b inactivator, binds to EAC43 to 1162  MODULATION  OF  THE  ALTERNATIVE  COMPLEMENT  PATHWAY 
limit the formation of EAC43--b-B and EAC43--~--BP, and in contrast to C3b inacti- 
vator,  it  increases  the  rate  of  loss  of  hemolytic  sites  from  EAC43--3"b-B and 
EAC43bBP.  For the C3b inactivator-potentiating effect, fllH and C3b inactiva- 
tor must necessarily be simultaneously present.  The kinetics of inactivation of 
C3b by C3b inactivator and fllH are first order, suggesting that potentiation is 
not a multistep process. The mechanisms of binding to C3b and inhibition of the 
alternative pathway convertases C3-b--~ and C3-~-~ are currently unknown. 
It is a pleasure to acknowledge the analytical ultracentrifuge studies of Dr. A. J. Richard. 
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